Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C

Dabbouseh, 2013, Future therapies for chronic hepatitis C, Nat Rev Gastroenterol Hepatol, 10, 268, 10.1038/nrgastro.2013.17

Liang, 2013, Current and future therapies for hepatitis C virus infection, N Engl J Med, 368, 1907, 10.1056/NEJMra1213651

Sarrazin, 2012, Antiviral strategies in hepatitis C virus infection, J Hepatol, 56, S88, 10.1016/S0168-8278(12)60010-5

Chung, 2014, Curing chronic hepatitis C—the arc of a medical triumph, N Engl J Med, 370, 1576, 10.1056/NEJMp1400986

Crespo, 2012, Viral hepatitis in liver transplantation, Gastroenterology, 142, 1373, 10.1053/j.gastro.2012.02.011

Garg, 2011, Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus, Hepatology, 54, 20, 10.1002/hep.24443

Charlton, 2011, Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents—a potentially lethal cocktail, Hepatology, 54, 3, 10.1002/hep.24470

Zeisel, 2013, Host-targeting agents for prevention and treatment of chronic hepatitis C—perspectives and challenges, J Hepatol, 58, 375, 10.1016/j.jhep.2012.09.022

Fafi-Kremer, 2010, Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation, J Exp Med, 207, 2019, 10.1084/jem.20090766

Fofana, 2012, Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies, Gastroenterology, 143, 223, 10.1053/j.gastro.2012.04.006

Zona, 2013, HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex, Cell Host Microbe, 13, 302, 10.1016/j.chom.2013.02.006

Sainz, 2012, Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor, Nat Med, 18, 281, 10.1038/nm.2581

Lupberger, 2011, EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy, Nat Med, 17, 589, 10.1038/nm.2341

Zahid, 2013, The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination, Hepatology, 57, 492, 10.1002/hep.26097

Lacek, 2012, Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice, J Hepatol, 57, 17, 10.1016/j.jhep.2012.02.018

Fofana, 2013, A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission, PLoS One, 8, e64221, 10.1371/journal.pone.0064221

Meuleman, 2008, Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo, Hepatology, 48, 1761, 10.1002/hep.22547

Syder, 2011, Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors, J Hepatol, 54, 48, 10.1016/j.jhep.2010.06.024

Haid, 2012, A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes, Gastroenterology, 143, 213, 10.1053/j.gastro.2012.03.036

Calland, 2012, (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry, Hepatology, 55, 720, 10.1002/hep.24803

Meuleman, 2011, Griffithsin has antiviral activity against hepatitis C virus, Antimicrob Agents Chemother, 55, 5159, 10.1128/AAC.00633-11

Fofana, 2010, Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes, Gastroenterology, 139, 953, 10.1053/j.gastro.2010.05.073

Lupberger, 2013, Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha, Hepatology, 58, 1225, 10.1002/hep.26404

Zhao, 2004, Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses, Clin Cancer Res, 10, 7994, 10.1158/1078-0432.CCR-04-1087

Prichard, 1990, A three-dimensional model to analyze drug-drug interactions, Antiviral Res, 14, 181, 10.1016/0166-3542(90)90001-N

Bauhofer, 2012, Persistence of HCV in quiescent hepatic cells under conditions of an interferon-induced antiviral response, Gastroenterology, 143, 429, 10.1053/j.gastro.2012.04.018

Pietschmann, 2009, Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations, PLoS Pathog, 5, e1000475, 10.1371/journal.ppat.1000475

Mercer, 2001, Hepatitis C virus replication in mice with chimeric human livers, Nat Med, 7, 927, 10.1038/90968

Wyles, 2007, Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets, J Virol, 81, 3005, 10.1128/JVI.02083-06

Jacobson, 2011, Telaprevir for previously untreated chronic hepatitis C virus infection, N Engl J Med, 364, 2405, 10.1056/NEJMoa1012912

Zeuzem, 2011, Telaprevir for retreatment of HCV infection, N Engl J Med, 364, 2417, 10.1056/NEJMoa1013086

Bacon, 2011, Boceprevir for previously treated chronic HCV genotype 1 infection, N Engl J Med, 364, 1207, 10.1056/NEJMoa1009482

Poordad, 2011, Boceprevir for untreated chronic HCV genotype 1 infection, N Engl J Med, 364, 1195, 10.1056/NEJMoa1010494

Reesink, 2010, Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients, Gastroenterology, 138, 913, 10.1053/j.gastro.2009.10.033

Gane, 2010, Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial, Lancet, 376, 1467, 10.1016/S0140-6736(10)61384-0

Gao, 2010, Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect, Nature, 465, 96, 10.1038/nature08960

Lok, 2012, Preliminary study of two antiviral agents for hepatitis C genotype 1, N Engl J Med, 366, 216, 10.1056/NEJMoa1104430

Chayama, 2012, Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders, Hepatology, 55, 742, 10.1002/hep.24724

Gane, 2013, Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C, N Engl J Med, 368, 34, 10.1056/NEJMoa1208953

Lawitz, 2013, Sofosbuvir for previously untreated chronic hepatitis C infection, N Engl J Med, 368, 1878, 10.1056/NEJMoa1214853

Jacobson, 2013, Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options, N Engl J Med, 368, 1867, 10.1056/NEJMoa1214854

Flisiak, 2009, The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients, Hepatology, 49, 1460, 10.1002/hep.22835

Himmelsbach, 2013, The kinase inhibitor Sorafenib impairs the antiviral effect of interferon alpha on hepatitis C virus replication, Eur J Cell Biol, 92, 12, 10.1016/j.ejcb.2012.09.001

Shi, 2013, Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice, Gut, 62, 1055, 10.1136/gutjnl-2012-302600

Lawitz, 2013, Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial, Lancet Infect Dis, 13, 401, 10.1016/S1473-3099(13)70033-1

Kowdley, 2013, Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial, Lancet, 381, 2100, 10.1016/S0140-6736(13)60247-0

Tong, 2014, In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir, J Infect Dis, 209, 668, 10.1093/infdis/jit562

Henrich, 2013, HIV-1 entry inhibitors: recent development and clinical use, Curr Opin Virol, 3, 51, 10.1016/j.coviro.2012.12.002

Shepherd, 2005, Erlotinib in previously treated non-small-cell lung cancer, N Engl J Med, 353, 123, 10.1056/NEJMoa050753

Matsumura, 2009, Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry, Gastroenterology, 137, 673, 10.1053/j.gastro.2009.04.048

Wagoner, 2010, Multiple effects of silymarin on the hepatitis C virus lifecycle, Hepatology, 51, 1912, 10.1002/hep.23587

Marino, 2013, Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period, J Hepatol, 58, 415, 10.1016/j.jhep.2012.09.034

Chung, 2013, Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study, Am J Transplant, 13, 1047, 10.1111/ajt.12083

Cataldo, 2011, Treatment of non-small-cell lung cancer with erlotinib or gefitinib, N Engl J Med, 364, 947, 10.1056/NEJMct0807960